Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toshihiko Doi

Showing results (41-50 of 247) with videos related to

Pageof 25
Sort By:
Investigational New Drugs|September 7, 2020
Correction to: Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancerShunsuke Kondo, Masaomi Tajimi, Tomohiko Funai, et al.
Cancer Chemotherapy and Pharmacology|November 6, 2012
Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumorsToshihiko Doi, Atsushi Ohtsu, Nozomu Fuse, et al.
Investigational New Drugs|June 25, 2020
Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancerShunsuke Kondo, Masaomi Tajimi, Tomohiko Funai, et al.
Investigational New Drugs|July 12, 2015
Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancerToshihiko Doi, Takayuki Yoshino, Nozomu Fuse, et al.
BMC Cancer|January 11, 2017
Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinomaKen Hatogai, Satoshi Fujii, Takashi Kojima, et al.
Molecular Cancer Therapeutics|October 25, 2024
Potential Mechanisms of Interstitial Lung Disease Induced by Antibody-Drug Conjugates Based on Quantitative Analysis of Drug DistributionShigehiro Koganemaru, Hirobumi Fuchigami, Chihiro Morizono, et al.
Cancer Chemotherapy and Pharmacology|May 4, 2016
A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumorsToshihiko Doi, Kohei Shitara, Takashi Kojima, et al.
Japanese Journal of Clinical Oncology|April 25, 2020
Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumorsKohei Shitara, Kentaro Yamazaki, Takahiro Tsushima, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|May 2, 2002
Extensive liver metastasis of gastric cancer effectively treated by hepatic arterial infusion of 5-fluorouracil/cisplatinAkio Moriya, Ichinosuke Hyodo, Tomohiro Nishina, et al.
Cancer Chemotherapy and Pharmacology|December 5, 2016
A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumorsToshihiko Doi, Nozomu Fuse, Takayuki Yoshino, et al.
Pageof 25

Showing results (41-50 of 247) with videos related to

Sort By:
Pageof 25
Investigational New Drugs|September 7, 2020
Correction to: Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancerShunsuke Kondo, Masaomi Tajimi, Tomohiko Funai, et al.
Cancer Chemotherapy and Pharmacology|November 6, 2012
Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumorsToshihiko Doi, Atsushi Ohtsu, Nozomu Fuse, et al.
Investigational New Drugs|June 25, 2020
Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancerShunsuke Kondo, Masaomi Tajimi, Tomohiko Funai, et al.
Investigational New Drugs|July 12, 2015
Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancerToshihiko Doi, Takayuki Yoshino, Nozomu Fuse, et al.
BMC Cancer|January 11, 2017
Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinomaKen Hatogai, Satoshi Fujii, Takashi Kojima, et al.
Molecular Cancer Therapeutics|October 25, 2024
Potential Mechanisms of Interstitial Lung Disease Induced by Antibody-Drug Conjugates Based on Quantitative Analysis of Drug DistributionShigehiro Koganemaru, Hirobumi Fuchigami, Chihiro Morizono, et al.
Cancer Chemotherapy and Pharmacology|May 4, 2016
A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumorsToshihiko Doi, Kohei Shitara, Takashi Kojima, et al.
Japanese Journal of Clinical Oncology|April 25, 2020
Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumorsKohei Shitara, Kentaro Yamazaki, Takahiro Tsushima, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|May 2, 2002
Extensive liver metastasis of gastric cancer effectively treated by hepatic arterial infusion of 5-fluorouracil/cisplatinAkio Moriya, Ichinosuke Hyodo, Tomohiro Nishina, et al.
Cancer Chemotherapy and Pharmacology|December 5, 2016
A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumorsToshihiko Doi, Nozomu Fuse, Takayuki Yoshino, et al.
Pageof 25